SUC

Newly Published Data Demonstrates Positive Outcomes Resulting from Pathnostics' Advanced Urinary Tract Infection (UTI) Test

Retrieved on: 
Tuesday, June 20, 2023

IRVINE, Calif., June 20, 2023 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced the publication of two new studies demonstrating positive outcomes resulting from its advanced urinary tract infection (UTI) test. The studies show that treatment based on the company's Guidance® UTI test resulted in decreased health care resource utilization and costs compared to standard urine culture (SUC) tests, as well as reduced antibiotic resistance in patients with complicated urinary tract infections.

Key Points: 
  • In fact, average one-year costs related to UTIs were $501.85 lower for patients receiving treatment based on the Guidance® test than for those based on the traditional culture test.
  • In addition, results showed patients diagnosed via the Guidance® test had improved outcomes, including fewer inpatient episodes and lower inpatient costs.
  • Separately, data published in the peer-reviewed journal Infection and Drug Resistance suggests that treatment based upon Guidance® UTI testing resulted in reduced antibiotic resistance in symptomatic patients with suspected complicated UTIs.
  • "These new findings, combined with ongoing studies, support our mission of increasing access to advanced UTI testing that supports more informed treatment leading to improved outcomes."

EpicQuest Education Announces Operations Update

Retrieved on: 
Thursday, January 5, 2023

MIDDLETOWN, Ohio, Jan. 5, 2023 /PRNewswire/ -- EpicQuest Education Group International Limited (NASDAQ: EEIQ), (the "Company" or "EpicQuest Education"), a provider of comprehensive education solutions for domestic and international students interested in college and university programs in the US, Canada and the UK, today announced an operations update.

Key Points: 
  • MIDDLETOWN, Ohio, Jan. 5, 2023 /PRNewswire/ -- EpicQuest Education Group International Limited (NASDAQ: EEIQ), (the "Company" or "EpicQuest Education"), a provider of comprehensive education solutions for domestic and international students interested in college and university programs in the US, Canada and the UK, today announced an operations update.
  • We believe that our strategic plan will optimally grow the company and lead to superior educational outcomes for our students," commented Jianbo Zhang, Chairman and CEO of EpicQuest Education.
  • An update of our owned and operated colleges as well as our recruiting relationship with the Miami University Regional Campuses follows.
  • EduGlobal College was approved for Education Quality Assurance (EQA) designation in British Columbia, Canada through May 31, 2023.

Labroots Announces 13th Annual Clinical Diagnostics & Research Virtual Event to be held on November 9th, 2022

Retrieved on: 
Thursday, November 3, 2022

YORBA LINDA, Calif., Nov. 3, 2022   /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event. On November 9th, an audience comprised of clinicians, research scholars, top scientists, academia and industry professionals and pharma and biotech will gather under a virtual roof to learn from recognized speakers driving innovation in diagnostics and precision medicine.

Key Points: 
  • Leading experts will explore advancements and new technologies in clinical diagnosis for early disease detection, treatment and prevention during this free, online event
    YORBA LINDA, Calif., Nov. 3, 2022 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event.
  • For over a decade, this online event has served as a premier meeting place for the clinical diagnostics, research and laboratory medicine communities.
  • And, once again Labroots' Clinical Diagnostics & Research 2022 will deliver on its commitment of breaking science in the areas of emerging diagnostic technologies, perspectives on SARS-CoV-2 and Monkeypox, precision medicine and special populations, and the lab's role in advancing equity.
  • Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Pathnostics to Present New Real-World Method to Identify and Evaluate Cost Outcomes of a Novel, Uncoded UTI Diagnostic at the International Society for Pharmacoeconomics and Outcomes Research 2022 Annual Meeting

Retrieved on: 
Monday, May 16, 2022

IRVINE, Calif., May 16, 2022 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present a new Medicare-claims-based method to identify an uncoded novel diagnostic (NDx), Guidance® UTI, and an analysis that found significantly lower costs as compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTIs). The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.

Key Points: 
  • The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.
  • Complicated urinary tract infections, which must be treated early and accurately to reduce the risk of poor outcomes, are a significant burden on individual health and healthcare resources.
  • Annually, UTIs contribute to 10.5 million office visits and carry a cost of approximately $3.5 billioni.
  • Details of the poster presentation are as follows:
    The abstract and poster are now available on the ISPOR 2022 Conference website.

New Real-World Evidence Shows Improvements in Outcomes and Reduction in Healthcare Costs with Guidance® UTI Precision Diagnostic Test Compared to Standard Urine Culture in Patients with Complicated Urinary Tract Infections

Retrieved on: 
Saturday, May 14, 2022

IRVINE, Calif., May 14, 2022 /PRNewswire/ -- Real-world evidence from a Medicare database analysis presented today at the 2022 American Urology Association (AUA) Meeting shows that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and costs for complicated urinary tract infections (cUTIs) compared to standard urine culture (SUC). The comparative analysis was designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC.

Key Points: 
  • The findings reinforce the real-world benefits of Guidance UTI's increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system."
  • UTI-related clinical, healthcare use and costs outcomes were then tracked for one year.
  • Guidance UTI testing was associated with 44% lower total costs and 77% lower clinically-advanced costs* compared to SUC, and cUTIs in the Guidance UTI cohort were likelier to be managed successfully as outpatients.
  • The rate of outpatient emergency visits was 13% lower and inpatient admissions were 67% lower when using Guidance UTI compared to SUC.

Pathnostics to Present New Real-World Data Analysis of its Guidance® UTI Precision Diagnostic Test at the 2022 American Urology Association Annual Meeting

Retrieved on: 
Tuesday, May 10, 2022

IRVINE, Calif., May 10, 2022 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present results of a Medicare database analysis designed to determine rates of adverse outcomes, medical resource utilization, and costs with Guidance UTI compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTI). These results will be presented at the 2022 American Urology Association (AUA) Meeting, taking place from May 13-16, in New Orleans, Louisiana.

Key Points: 
  • These results will be presented at the 2022 American Urology Association (AUA) Meeting, taking place from May 13-16, in New Orleans, Louisiana.
  • Annually, UTIs contribute to 10.5 million office visits and carry a cost of approximately $3.5 billioni.
  • Guidance UTI is an advanced test that combines PCR and Pooled Antibiotic Susceptibility Testing (P-AST), which better address polymicrobial infections where bacterial interactions can impact antibiotic resistance.
  • Pathnostics is a leading precision diagnostic testing and development company providing solutions for infectious disease and cancer diagnostics that will get patients on the right path.